Logo image of SNGX

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SNGX - US8342236044 - Common Stock

1.6245 USD
+0.02 (+1.53%)
Last: 12/11/2025, 9:48:33 AM
Fundamental Rating

2

SNGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. The financial health of SNGX is average, but there are quite some concerns on its profitability. SNGX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNGX has reported negative net income.
In the past year SNGX has reported a negative cash flow from operations.
SNGX had negative earnings in each of the past 5 years.
SNGX had a negative operating cash flow in each of the past 5 years.
SNGX Yearly Net Income VS EBIT VS OCF VS FCFSNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -101.45%, SNGX is doing worse than 76.27% of the companies in the same industry.
The Return On Equity of SNGX (-150.79%) is worse than 65.16% of its industry peers.
Industry RankSector Rank
ROA -101.45%
ROE -150.79%
ROIC N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNGX Yearly ROA, ROE, ROICSNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNGX Yearly Profit, Operating, Gross MarginsSNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNGX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SNGX has more shares outstanding
The debt/assets ratio for SNGX has been reduced compared to a year ago.
SNGX Yearly Shares OutstandingSNGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SNGX Yearly Total Debt VS Total AssetsSNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -30.22, we must say that SNGX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -30.22, SNGX is not doing good in the industry: 89.83% of the companies in the same industry are doing better.
There is no outstanding debt for SNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -30.22
ROIC/WACCN/A
WACC8.92%
SNGX Yearly LT Debt VS Equity VS FCFSNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 3.18 indicates that SNGX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.18, SNGX is doing worse than 63.09% of the companies in the same industry.
SNGX has a Quick Ratio of 3.18. This indicates that SNGX is financially healthy and has no problem in meeting its short term obligations.
SNGX's Quick ratio of 3.18 is on the low side compared to the rest of the industry. SNGX is outperformed by 60.26% of its industry peers.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
SNGX Yearly Current Assets VS Current LiabilitesSNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

SNGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.38%, which is quite impressive.
Looking at the last year, SNGX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
The Revenue for SNGX have been decreasing by -51.88% on average. This is quite bad
EPS 1Y (TTM)58.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SNGX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.74% on average per year.
Based on estimates for the next years, SNGX will show a small growth in Revenue. The Revenue will grow by 6.88% on average per year.
EPS Next Y60.35%
EPS Next 2Y36.53%
EPS Next 3Y22.74%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SNGX Yearly Revenue VS EstimatesSNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2M 4M 6M 8M 10M
SNGX Yearly EPS VS EstimatesSNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNGX Price Earnings VS Forward Price EarningsSNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNGX Per share dataSNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

SNGX's earnings are expected to grow with 22.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.53%
EPS Next 3Y22.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLIGENIX INC

NASDAQ:SNGX (12/11/2025, 9:48:33 AM)

1.6245

+0.02 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)03-19 2026-03-19/amc
Inst Owners13.23%
Inst Owner Change632.36%
Ins Owners0.16%
Ins Owner Change0.5%
Market Cap16.39M
Revenue(TTM)N/A
Net Income(TTM)-11.46M
Analysts82.86
Price Target17.85 (998.8%)
Short Float %4.35%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.08%
Min EPS beat(2)-2.46%
Max EPS beat(2)12.62%
EPS beat(4)1
Avg EPS beat(4)-15.65%
Min EPS beat(4)-55.11%
Max EPS beat(4)12.62%
EPS beat(8)4
Avg EPS beat(8)-1.7%
EPS beat(12)7
Avg EPS beat(12)-11.59%
EPS beat(16)9
Avg EPS beat(16)-10.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.22%
EPS NQ rev (1m)31.48%
EPS NQ rev (3m)31.48%
EPS NY rev (1m)15.48%
EPS NY rev (3m)15.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 2.16
EV/EBITDA N/A
EPS(TTM)-3.6
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.45%
ROE -150.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z -30.22
F-Score3
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
EPS Next Y60.35%
EPS Next 2Y36.53%
EPS Next 3Y22.74%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A
EBIT growth 1Y-57.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.3%
OCF growth 3YN/A
OCF growth 5YN/A

SOLIGENIX INC / SNGX FAQ

Can you provide the ChartMill fundamental rating for SOLIGENIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to SNGX.


Can you provide the valuation status for SOLIGENIX INC?

ChartMill assigns a valuation rating of 1 / 10 to SOLIGENIX INC (SNGX). This can be considered as Overvalued.


What is the profitability of SNGX stock?

SOLIGENIX INC (SNGX) has a profitability rating of 0 / 10.


What is the expected EPS growth for SOLIGENIX INC (SNGX) stock?

The Earnings per Share (EPS) of SOLIGENIX INC (SNGX) is expected to grow by 60.35% in the next year.